Company news
Bioarctic Ab Class B (OMXSTO:BIOA_B) news
Every Bioarctic Ab Class B press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BioArctic publishes the Annual Report and Sustainability Report for 2025
April 21, 2026
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
March 27, 2026
Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
March 11, 2026
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
February 27, 2026
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
February 11, 2026
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
February 9, 2026
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
February 6, 2026
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
January 26, 2026
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review ...
January 25, 2026
BLA for subcutaneous formulation of Leqembi® accepted in China
January 6, 2026
Leqembi included in China's commercial insurance innovative drug list
December 8, 2025
Interim Report for the period July - September 2025: BioArctic
November 13, 2025
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
November 4, 2025
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
October 30, 2025
Health Canada Grants Authorization for Leqembi® (lecanemab)
October 26, 2025
First patient treated with Leqembi® (lecanemab) in the Nordics
October 14, 2025
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
October 6, 2025
Leqembi® approved for IV maintenance treatment in China
September 29, 2025
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
September 24, 2025
BioArctic's founders intend to divest minor part of their shareholding
September 3, 2025
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Al...
September 2, 2025
US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's di...
August 29, 2025
BioArctic: Interim Report for the period April - June 2025
August 28, 2025
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 milli...
August 26, 2025
Leqembi® (lecanemab) launched in the EU today
August 25, 2025
Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
August 21, 2025
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
July 31, 2025
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
July 16, 2025
BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
June 26, 2025
BioArctic's Capital Markets Day 2025 - entering a new era of growth
June 2, 2025
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
May 15, 2025